BEERSE, BELGIUM, 8 October 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced further findings for SPRAVATO® (esketamine nasal spray [NS]) from the ESCAPE-TRD study. Data on treatment-emergent adverse events (TEAEs) suggest a more favourable tolerability profile in adults with treatment-resistant major depressive disorder (TRD) receiving esketamine NS than quetiapine XR. Across all reported TEAEs experienced with esketamine NS, 92.1 percent were transient and resolved the same-day vs 12.1 percent of TEAEs experienced with quetiapine XR.1 The findings were presented at the 36th European College of Neuropsychopharmacology Congress (ECNP 2023) taking place from 7 October to 10 October in Barcelona, Spain.
FDA Confirms Paragraph IV Patent Litigation for Esketamine Hydrochloride
(Yicai Global) April 21 -- China has given the green light to the local unit of Janssen Pharmaceuticals, owned by US medical device and drug developer Johnson & Johnson, to market its new antidepressant in the country.
New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO®▼(Esketamine Nasal Spray [NS]) Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release
Janssen’s SPRAVATO® (esketamine nasal spray [NS]) helped more participants with treatment-resistant major depressive disorder (TRD) remain remission and relapse free compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), in a Phase III trial (04338321).
The Janssen Pharmaceutical Companies of Johnson & Johnson has reported that the Phase IIIb ESCAPE-TRD clinical trial of Spravato (esketamine nasal spray [NS]) for treatment-resistant major depressive disorder (TRD) in adult patients met its primary endpoint.
Johnson & Johnson’s esketamine nasal spray continues to build a body of evidence showing it can go toe-to-toe with tough-to-treat depression.
SPRAVATO®? (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1
Each of these new therapies has a proposed rationale for its utility. Ketamine and its molecular sister esketamine increase the effect of glutamate, the most widespread natural chemical stimulant in the brain. Cannabis binds to a series of receptors for its active ingredients, tetrahydrocannabinol and cannabidiol existent in the brain.
The work of the U.K.’s drug pricing watchdog naturally ruffles the pharma industry’s feathers from time to time, though formal attempts to parry its appraisals rarely pan out for drugmakers.